Sanofi's LixiLan Phase III studies meet primary endpoints

French pharma major Sanofi (Euronext: SAN) has announced that two late-stage Phase III trials of its LixiLan diabetes drugs have met their primary endpoints.

Full results of the LixiLan-O and the LixiLan-L trials with the investigational titratable fixed-ratio combination of basal insulin glargine U-100 (marketed as Lantus) and GLP-1 receptor agonist lixisenatide (approved in some countries under the trade name of Lyxumia) in adults with type 2 diabetes were presented at the American Diabetes Association 76th Scientific Sessions in New Orleans, USA.

Both studies met their primary endpoints, demonstrating statistically superior reduction of HbA1c (average blood glucose over the previous three months) with the titratable fixed-ratio combination versus insulin glargine or lixisenatide alone, the company said in a statement.